A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia
Completed
Hoffmann-La Roche
Phase 3
This Phase 3, multi-center, randomized, double blind, parallel-group, placebo-controlled
study will evaluate the efficacy and safety of RO4917838 (bitopertin) in participants with
persistent, predominant negative symptoms of schizophrenia. Participants, on stable treatment
with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching
placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
Completed
Hoffmann-La Roche
Phase 3
This multi-center, randomized, double blind, parallel-group, placebo-controlled study will
evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with persistent,
predominant negative symptoms of schizophrenia. Patients, on stable treatment with
antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching
placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.
A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia
Completed
Hoffmann-La Roche
Phase 2
This randomized, double-blind, placebo- and active-controlled, parallel group study will
evaluate the safety and efficacy of RO4917838 (bitopertin) in patients with acute
exacerbation of schizophrenia. Patients will be randomized to receive either RO4917838 10 mg
or RO4917838 30 mg or olanzapine 15 mg or placebo orally daily for 4 weeks as inpatients,
with a 4-week follow-up period.
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)
Completed
Hoffmann-La Roche
Phase 3
This randomized, multi-center double-blind, parallel-group, placebo-controlled study will
evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with sub-optimally
controlled symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will
be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks,
followed by an optional treatment extension for up to 3 years.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
